Final follow-up of a Phase I dose-ranging study of Bendamustine and Rituximab (BR) in patients with chronic lymphocytic leukemia (CLL) with comorbidities

被引：0
|
作者：
Danilov, Alexey [1 ]
Lewis, Lionel [2 ]
Brown, Jennifer [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Dartmouth Coll, Hanover, NH USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
17
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [41] Phase-II-study of rituximab in combination with fludarabine in patients (pts) with chronic lymphocytic leukemia (CLL).
    Schulz, H
    Klein, SK
    Rehwald, U
    Reiser, M
    Ibach, S
    Aulitzky, WE
    Hensel, M
    Herold, M
    Huhn, D
    Knauf, U
    Hallek, M
    Diehl, V
    Engert, A
    BLOOD, 2001, 98 (11) : 364A - 364A
  • [42] Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial
    Cramer, Paula
    Chanan-Khan, Asher
    Fraser, Graeme
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Goy, Andre
    Mayer, Jiri
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Barlett, Nancy
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Phelps, Charles
    Mahler, Michelle
    Salman, Masha
    Howes, Angela
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2015, 56 : 93 - 94
  • [43] Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL).
    O'Brien, S
    Freireich, E
    Andreeff, M
    Lerner, S
    Keating, M
    BLOOD, 1998, 92 (10) : 105A - 105A
  • [44] ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    de la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abe
    Avery, E. J.
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    LEUKEMIA & LYMPHOMA, 2020, 61 : 235 - 237
  • [45] Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Hebart, Holger
    Ghia, Paolo
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kryachok, Irina
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Patel, Priti
    Quah, Cheng
    Liang, Wei
    Lee, Jae Hoon
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 128 - 129
  • [46] Acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at ∼4 years of follow-up
    Welslau, M.
    Jurczak, W.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Simkovic, M.
    Kriachok, I
    Illes, A.
    De la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Hoon, Lee J.
    Usenko, G.
    Wang, M. H.
    Yu, T.
    Ghia, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 118 - 119
  • [47] Acalabrutinib vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Results at ∼4 Years of Follow-up
    Welslau, Manfred
    Jurczak, Wojciech
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Simkovic, Martin
    Kryachok, Irina
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric
    Lee, Jae Hoon
    Usenko, Ganna
    Wang, Min Hui
    Yu, Ting
    Ghia, Paolo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 170
  • [48] A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
    J A Woyach
    T S Lin
    M S Lucas
    N Heerema
    M E Moran
    C Cheney
    D M Lucas
    L Wei
    M A Caligiuri
    J C Byrd
    Leukemia, 2009, 23 : 912 - 918
  • [49] A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
    Woyach, J. A.
    Lin, T. S.
    Lucas, M. S.
    Heerema, N.
    Moran, M. E.
    Cheney, C.
    Lucas, D. M.
    Wei, L.
    Caligiuri, M. A.
    Byrd, J. C.
    LEUKEMIA, 2009, 23 (05) : 912 - 918
  • [50] Phase 3 zanubrutinib (BGB-3111) vs bendamustine plus rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Hillmen, Peter
    Brown, Jennifer R.
    Kahl, Brad S.
    Ghia, Paolo
    Robak, Tadeusz
    Marimpietri, Carol
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine Si Lun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345